Compare GVA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GVA | FOLD |
|---|---|---|
| Founded | 1922 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 1995 | 2006 |
| Metric | GVA | FOLD |
|---|---|---|
| Price | $123.00 | $14.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $118.33 | $27.25 |
| AVG Volume (30 Days) | 588.3K | ★ 2.7M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | 47.33 | ★ 50.00 |
| EPS | ★ 3.86 | N/A |
| Revenue | ★ $1,762,965,000.00 | N/A |
| Revenue This Year | $13.46 | $20.50 |
| Revenue Next Year | $6.83 | $18.59 |
| P/E Ratio | $31.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $69.08 | $5.66 |
| 52 Week High | $137.24 | $14.39 |
| Indicator | GVA | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 69.55 |
| Support Level | $116.73 | $14.21 |
| Resistance Level | $124.99 | N/A |
| Average True Range (ATR) | 3.37 | 0.02 |
| MACD | -1.56 | -0.02 |
| Stochastic Oscillator | 13.12 | 78.57 |
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.